Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment
Public ClinicalTrials.gov record NCT02573740. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Study to Evaluate the Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of Multiple Doses of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment Due to Alzheimer's Disease
Study identification
- NCT ID
- NCT02573740
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 8 participants
Conditions and interventions
Conditions
Interventions
- ABT-957 Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 55 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2015
- Primary completion
- May 31, 2016
- Completion
- May 31, 2016
- Last update posted
- Jul 5, 2021
2015 – 2016
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator# 143180 | Cypress | California | 90630 | — |
| Site Reference ID/Investigator# 143178 | Orlando | Florida | 32806 | — |
| Site Reference ID/Investigator# 149484 | The Villages | Florida | 32162 | — |
| Site Reference ID/Investigator# 143181 | Marlton | New Jersey | 08053 | — |
| Site Reference ID/Investigator# 143182 | Cincinnati | Ohio | 45255 | — |
| Site Reference ID/Investigator# 149481 | Dallas | Texas | 75231 | — |
| Site Reference ID/Investigator# 143254 | Orem | Utah | 84058 | — |
| Site Reference ID/Investigator# 143179 | Salt Lake City | Utah | 84107 | — |
| Site Reference ID/Investigator# 143177 | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02573740, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 5, 2021 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02573740 live on ClinicalTrials.gov.